This Article Full Text Full Text (PDF) All Versions of this Article: 40/2/663    most recent STROKEAHA.108.525352v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Martin-Schild, S. Articles by Savitz, S. I. Search for Related Content PubMed PubMed Citation Articles by Martin-Schild, S. Articles by Savitz, S. I. Related Collections Acute Cerebral Infarction Thrombolysis

(Stroke. 2009;40:663.)
© 2009 American Heart Association, Inc.

Research Letters

Does Study Enrollment Delay Treatment With Intravenous Thrombolytics for Acute Ischemic Stroke?

Sheryl Martin-Schild, MD, PhD; Karen C. Albright, MD; Hen Hallevi, MD; Andrew D. Barreto, MD; James C. Grotta, MD Sean I. Savitz, MD

From the Department of Neurology (S.M.-S., H.H., A.D.B., J.C.G., S.I.S.), University of Texas, Houston Medical School, Houston, Texas; and the Department of Neurology (K.C.A.), UCSD, San Diego, Calif.

Correspondence to Sean I. Savitz, MD, Department of Neurology, University of Texas Medical School at Houston, Houston, TX 77030. E-mail sean.i.savitz{at}uth.tmc.edu

Background and Purpose— Enrollment in acute stroke trials at a stroke center with multiple study protocols may delay the initiation of intravenous thrombolytics in patients who present within 3 hours of symptom onset.

Methods— We studied all patients presenting with acute ischemic stroke over the past 3.5 years who qualified for thrombolysis within 3 hours of symptom onset. We collected demographics, baseline National Institutes of Health Stroke Scale scores, CT findings, and arrival-to-treatment times and compared patients treated with intravenous thrombolytics in a clinical trial with patients who received standard of care intravenous tissue plasminogen activator.

Results— Of 290 treated patients, 19 were enrolled in prelytic studies, 46 were enrolled in postlytic studies, and 225 were treated with standard intravenous tissue plasminogen activator. There was no significant difference in age, gender, National Institutes of Health Stroke Scale score, admission glucose, or changes on CT. There was no difference in onset-to-arrival time or arrival-to-treatment time between patients enrolled in clinical studies and those who received standard treatment. However, among study patients, prelytic randomization led to a significantly longer arrival-to-treatment time by 13 minutes (P=0.028).

Conclusion— We found that trials requiring prethrombolytic randomization can lead to a delay in the initiation of treatment. Future studies are needed to determine if such a delay is clinically significant and can be shortened by improved enrollment strategies.

Key Words: acute stroke • clinical trials • thrombolytic treatment